You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
A 50% decline in a blue-chip share can signal trouble, but not always a broken story. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services.
In July 2024, we listened to the Labour government’s first King’s Speech. It contained a single line almost imperceptibly nodding towards something on artificial intelligence (AI). The government said ...
CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...
Court rules not all computer code is protected under First Amendment's free speech shield Gun website loses bid to revive lawsuit over ghost gun code Lawsuit followed New Jersey crackdown on ghost ...
CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...
Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...
CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...
Joe Grantham is a contributor from the UK with a degree in Classical Studies. His love for gaming is only rivaled by a deep passion for medieval history, which often seeps into his articles. With over ...
A divided three-judge panel of the Ninth Circuit Court of Appeals ruled that the University of Washington violated a computer science professor’s First Amendment rights when it investigated and ...
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...
SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results